ANXA1 and plasma cell myeloma: In some patients, BCMA-negative relapse has been associated with upregulation of annexin A1 (ANXA1), a molecule that promotes myeloma growth and disrupts CAR-T targeting; preclinical inhibition of ANXA1 restores CAR-T sensitivity [128].